Related Experiment Videos
[A survey on the status of lipid-lowering therapy in 180 hypercholesterolemic patients]
Siyu Cai1, Shunying Xia, Haibao Xie
1Department of Cardiology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
Insights
Many hypercholesterolemic patients on lipid-lowering therapy do not meet total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) targets. This highlights a gap in clinical practice, indicating a need for more aggressive dyslipidemia management.
Area of Science:
- Cardiology
- Endocrinology
- Public Health
Context:
- Hypercholesterolemia management is crucial for cardiovascular disease prevention.
- Chinese National Recommendations provide targets for total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C).
- Lipid-lowering therapies are widely prescribed for hypercholesterolemic patients.
Purpose:
- To assess the proportion of hypercholesterolemic patients achieving target TC and LDL-C levels.
- To evaluate treatment success rates based on cardiovascular risk stratification.
- To compare the effectiveness of different lipid-lowering drug classes.
Summary:
- This study evaluated 180 adult hypercholesterolemic patients on stable lipid-lowering therapy.
- Only 44% achieved recommended TC and LDL-C targets, with lower success in high-risk groups (atherosclerosis/diabetes).
- Simvastatin showed the highest success rate (51.8%) among investigated statins.
Impact:
- Findings reveal a significant gap between dyslipidemia guidelines and clinical practice in China.
- Suggests a need for intensified therapeutic strategies to improve lipid control.
- Highlights potential for optimizing statin selection and adherence for better patient outcomes.
Objective:
To determine the percentage of hypercholesterolemic patients who had met the criteria as total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), defined by the Chinese National Recommendations for Prevention and Treatment of Dyslipidemia.
Methods:
Adult patients with hypercholesterolemia, who had been receiving the same lipid-lowering therapy for at least 2 months, were enrolled. Lipid levels were determined at the time of enrollment, to assess whether the patients' lipid levels had reached the criteria for treatment. Patients' cardiovascular risk factors and lipid-lowering treatments were also collected.
Results:
One hundred and eighty patients with mean age of 65.8 were studied. Of these, 6.7% had no risk factors and no definite disease of atherosclerosis (low-risk group), 65.5% had risk factors but no documented atherosclerosis (high-risk group), and 27.8% had established atherosclerosis diseases or diabetes mellitus. Overall, only 44% of patients achieved both TC and LDL-C target levels. The success rates were higher among low and high-risk groups than that among patients with atherosclerosis or diabetes mellitus. The relationship between four different lipid-lowering drug therapies and successful patient outcome was also investigated. The success rates were 51.8% for simvastatin, 42.9% for pravastatin, 31.6% for fluvastatin, 12.5% for other drugs respectively.
Conclusion:
More than half of the hypercholesterolemic patients receiving lipid-lowering therapy had not achieved TC and LDL-C target levels. Data from this study indicated that a significant gap still existed between dyslipidemia prevention principles and clinical practices, suggesting that more aggressive treatment of dyslipidemia is needed.